Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Alzheimer's and Dementia
Journal
Overview
Overview
Publication Venue For
Potential long-term effect of tumor necrosis factor inhibitors on dementia risk: A propensity score matched retrospective cohort study in US veterans.
. 18:1248-1259.
2022
The association of motoric cognitive risk with incident dementia and neuroimaging characteristics: The Atherosclerosis Risk in Communities Study
. 18:434-444.
2022
Association between cancer treatment and progression of all-cause dementia
. 17:e054164.
2021
Dementia care in diverse older adults in the Deep South and the rest of the United States
. 17:e054038.
2021
Demographic and psychosocial factors associated with the decision to learn mutation status in familial frontotemporal dementia and the impact of disclosure on mood
. 17:e050692.
2021
Developing a functionally valid model of the TREM2-APOE complex to better understand its role in Alzheimer's disease
. 17:e056092.
2021
Exome sequencing identifies rare damaging variants in the ATB8B4 and ABCA1 genes as novel risk factors for Alzheimer's disease
. 17:e055982.
2021
Factors influencing medication adherence among U.S. Medicare beneficiaries with Alzheimer’s disease and related dementia (ADRD)
. 17.
2021
Gearing up for the future: Exploring facilitators and barriers to inform clinical trial design in frontotemporal lobar degeneration
. 17:e052495.
2021
Identification of cis-regulatory elements associated with MAPT expression in human induced pluripotent stem cell derived neural cells
. 17:e058349.
2021
Modeling AD-related metabolic impairments in the TgF344-AD rat model
. 17:e058576.
2021
Functional insights from biophysical study of TREM2 interactions with apoE and Aβ
1-42
. 17:475-488.
2021
Daily stressful experiences, depressive symptoms, and behavioral responses of ADRD family caregivers
. 16.
2020
Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration
. 16:91-105.
2020
Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint
. 16:11-21.
2020
Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint.
. 16:11-21.
2020
Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration
. 16:49-59.
2020
Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort
. 16:60-70.
2020
Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases
. 16:118-130.
2020
Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration
. 16:37-48.
2020
Use of the CDR® plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium
. 16:79-90.
2020
Utility of the global CDR
®
plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium
. 16:106-117.
2020
Genetic origin of a large family with a novel PSEN1 mutation (Ile416Thr)
. 15:709-719.
2019
Leisure-time physical activity sustained since midlife and preservation of cognitive function: The Atherosclerosis Risk in Communities Study
. 15:273-281.
2019
Transethnic genome-wide scan identifies novel Alzheimer's disease loci
. 13:727-738.
2017
Glucose level decline precedes dementia in elderly African Americans with diabetes
. 13:111-118.
2017
Global and local ancestry in African-Americans: Implications for Alzheimer's disease risk
. 12:233-243.
2016
Genetically predicted body mass index and Alzheimer's disease-related phenotypes in three large samples: Mendelian randomization analyses
. 11:1439-1451.
2015
O3‐06‐01: Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease
. 11.
2015
Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease
. 10:349-359.
2014
Implications of early treatment among Medicaid patients with Alzheimer's disease
. 10:214-224.
2014
Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development
. 9:176-188.
2013
The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)
. 9:189-198.
2013
Erratum: Estimating power with effect size versus slope differences: Both means and variance matter (Alzheimer's and Dementia (2011) 7 (247-249))
. 7:556.
2011
Estimating power with effect size versus slop differences: Both means and variance matter
. 7:247-249.
2011
Requiring an amyloid-β
1-42
biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials
. 6:367-377.
2010
Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia
. 4:421-427.
2008